The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: An ACTION registry analysis

Published:September 19, 2022DOI:


      Cardiac disease results in significant morbidity and mortality in patients with muscular dystrophy (MD). Single centers have reported their ventricular assist device (VAD) experience in specific MDs and in limited numbers. This study sought to describe the outcomes associated with VAD therapy in an unselected population across multiple centers.


      We examined outcomes of patients with MD and dilated cardiomyopathy implanted with a VAD at Advanced Cardiac Therapies Improving Outcomes Network (ACTION) centers from 9/2012 to 9/2020.


      A total of 19 VADs were implanted in 18 patients across 12 sites. The majority of patients had dystrophinopathy (66%) and the median age at implant was 17.2 years (range 11.7-29.5). Eleven patients were non-ambulatory (61%) and 6 (33%) were on respiratory support pre-VAD. Five (28%) patients were implanted as a bridge to transplant, 4 of whom survived to transplant. Of 13 patients implanted as bridge to decision or destination therapy, 77% were alive at 1 year and 69% at 2 years. The overall frequencies of positive outcome (transplanted or alive on device) at 1 year and 2 years were 84% and 78%, respectively. Two patients suffered a stroke, 2 developed sepsis, 1 required tracheostomy, and 1 experienced severe right heart failure requiring right-sided VAD.


      This study demonstrates the potential utility of VAD therapies in patients with muscular dystrophy. Further research is needed to further improve outcomes and better determine which patients may benefit most from VAD therapy in terms of survival and quality of life.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Feingold B
        • Mahle WT
        • Auerbach S
        • et al.
        Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association.
        Circulation. 2017; 136: e200-e231
        • Eagle M
        • Baudouin SV
        • Chandler C
        • Giddings DR
        • Bullock R
        • Bushby K.
        Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.
        Neuromuscul Disord NMD. 2002; 12: 926-929
        • Iodice F
        • Testa G
        • Averardi M
        • Brancaccio G
        • Amodeo A
        • Cogo P.
        Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy patients with end stage cardiac failure: management and lessons learned.
        Neuromuscul Disord NMD. 2015; 25: 19-23
        • Ryan TD
        • Jefferies JL
        • Sawnani H
        • et al.
        Implantation of the HeartMate II and HeartWare left ventricular assist devices in patients with Duchenne muscular dystrophy: lessons learned from the first applications.
        ASAIO J. 2014; 60: 246-248
        • Cripe LH
        • Barber BJ
        • Spicer RL
        • et al.
        Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy.
        Neuromuscul Disord NMD. 2006; 16: 745-748
        • Morales DLS
        • Adachi I
        • Peng DM
        • et al.
        Fourth annual pediatric interagency registry for mechanical circulatory support (pedimacs) report.
        Ann Thorac Surg. 2020; 110: 1819-1831
        • Perri G
        • Filippelli S
        • Adorisio R
        • et al.
        Left ventricular assist device as destination therapy in cardiac end-stage dystrophinopathies: midterm results.
        J Thorac Cardiovasc Surg. 2017; 153: 669-674
        • Stoller D
        • Araj F
        • Amin A
        • et al.
        Implantation of a left ventricular assist device to provide long-term support for end-stage Duchenne muscular dystrophy-associated cardiomyopathy: LVAD support for DMD-associated cardiomyopathy.
        ESC Heart Fail. 2017; 4: 379-383
        • Lorts A
        • Smyth L
        • Gajarski RJ
        • et al.
        The creation of a pediatric health care learning network: the ACTION quality improvement collaborative.
        ASAIO J Am Soc Artif Intern Organs 1992. 2020; 66: 441-446
        • Cook JL
        • Colvin M
        • Francis GS
        • et al.
        Recommendations for the use of mechanical circulatory support: ambulatory and community patient care: a scientific statement from the American Heart Association.
        Circulation. 2017; 135: e1145-e1158
        • Villa C
        • Auerbach SR
        • Bansal N
        • et al.
        Current practices in treating cardiomyopathy and heart failure in Duchenne muscular dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through ACTION.
        Pediatr Cardiol. 2022; 43: 977-985
        • Cheeran D
        • Khan S
        • Khera R
        • et al.
        Predictors of death in adults with Duchenne muscular dystrophy-associated cardiomyopathy.
        J Am Heart Assoc. 2017; 6e006340
        • Wittlieb-Weber CA
        • Knecht KR
        • Villa CR
        • et al.
        Risk factors for cardiac and non-cardiac causes of death in males with Duchenne muscular dystrophy.
        Pediatr Cardiol. 2020; 41: 764-771
        • Fayssoil A
        • Nardi O
        • Orlikowski D
        • Annane D.
        Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.
        Heart Fail Rev. 2010; 15: 103-107
        • Wittlieb-Weber CA
        • Villa CR
        • Conway J
        • et al.
        Use of advanced heart failure therapies in Duchenne muscular dystrophy.
        Prog Pediatr Cardiol. 2019; 53: 11-14
        • O'Connor MJ
        • Lorts A
        • Davies RR
        • et al.
        Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: a multicenter registry analysis.
        J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2020; 39: 573-579
        • Rossano JW
        • VanderPluym CJ
        • Peng DM
        • et al.
        Fifth annual pediatric interagency registry for mechanical circulatory support (pedimacs) report.
        Ann Thorac Surg. 2021; 112: 1763-1774
        • Shah P
        • Yuzefpolskaya M
        • Hickey GW
        • et al.
        Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: readmissions after left ventricular assist device.
        Ann Thorac Surg. 2022; 113: 722-737
        • Auerbach SR
        • Simpson KE
        • Action Learning Network Investigators
        HVAD usage and outcomes in the current pediatric ventricular assist device field: an advanced cardiac therapies improving outcomes network (ACTION) analysis.
        ASAIO J Am Soc Artif Intern Organs 1992. 2021; 67: 675-680
        • Yates K
        • Festa M
        • Gillis J
        • Waters K
        • North K.
        Outcome of children with neuromuscular disease admitted to paediatric intensive care.
        Arch Dis Child. 2004; 89: 170-175
        • Frank AO
        • De Souza LH.
        Clinical features of children and adults with a muscular dystrophy using powered indoor/outdoor wheelchairs: disease features, comorbidities and complications of disability.
        Disabil Rehabil. 2018; 40: 1007-1013
        • Schram G
        • Fournier A
        • Leduc H
        • et al.
        All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.
        J Am Coll Cardiol. 2013; 61: 948-954
        • McDonald CM
        • Gordish-Dressman H
        • Henricson EK
        • et al.
        Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids.
        Neuromuscul Disord NMD. 2018; 28: 897-909
        • Ben Yaou R
        • Yun P
        • Dabaj I
        • et al.
        International retrospective natural history study of LMNA-related congenital muscular dystrophy.
        Brain Commun. 2021; 3fcab075
        • Van Ruiten HJA
        • Marini Bettolo C
        • Cheetham T
        • et al.
        Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England.
        Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2016; 20: 904-909
        • Kieny P
        • Chollet S
        • Delalande P
        • et al.
        Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011.
        Ann Phys Rehabil Med. 2013; 56: 443-454
        • Fayssoil A
        • Yaou RB
        • Ogna A
        • et al.
        Clinical profiles and prognosis of acute heart failure in adult patients with dystrophinopathies on home mechanical ventilation.
        ESC Heart Fail. 2017; 4: 527-534
        • Mehmood M
        • Ambach SA
        • Taylor MD
        • et al.
        Relationship of right ventricular size and function with respiratory status in Duchenne muscular dystrophy.
        Pediatr Cardiol. 2016; 37: 878-883
        • Sawnani H
        • Horn PS
        • Wong B
        • et al.
        Comparison of pulmonary function decline in steroid-treated and steroid-naïve patients with Duchenne muscular dystrophy.
        J Pediatr. 2019; 210: 194-200.e2
        • Cha JJ
        • Kim IS
        • Kim JY
        • et al.
        The association between cardiac involvement and long-term clinical outcomes in patients with Duchenne muscular dystrophy.
        ESC Heart Fail. 2022; 9: 2199-2206
        • Wahlgren L
        • Kroksmark AK
        • Tulinius M
        • Sofou K.
        One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure.
        Eur J Epidemiol. 2022; 37: 147-156
        • Hershberger RE
        • Hedges DJ
        • Morales A.
        Dilated cardiomyopathy: the complexity of a diverse genetic architecture.
        Nat Rev Cardiol. 2013; 10: 531-547
        • Bauer WM
        • Mallory H.
        I Have Muscular Dystrophy, And It's Okay!.
        WestBow Press, 2021
      1. Muscular dystrophy patients teach you about their VADs! (ACTION Learning Network) - YouTube. Accessed April 18, 2022.

        • Green CP
        • Porter CB
        • Bresnahan DR
        • Spertus JA.
        Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.
        J Am Coll Cardiol. 2000; 35: 1245-1255
        • Uzark K
        • King E
        • Cripe L
        • et al.
        Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.
        Pediatrics. 2012; 130: e1559-e1566
        • Powell PA
        • Carlton J
        • Woods HB
        • Mazzone P.
        Measuring quality of life in Duchenne muscular dystrophy: a systematic review of the content and structural validity of commonly used instruments.
        Health Qual Life Outcomes. 2020; 18: 263
        • Powell PA
        • Carlton J
        • Rowen D
        • Chandler F
        • Guglieri M
        • Brazier JE.
        Development of a new quality of life measure for Duchenne muscular dystrophy using mixed methods: the DMD-QoL.
        Neurology. 2021; 96: e2438-e2450
        • Szabo SM
        • Audhya IF
        • Malone DC
        • Feeny D
        • Gooch KL.
        Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review.
        Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2020; 29: 593-605
        • Rizzieri AG
        • Verheijde JL
        • Rady MY
        • McGregor JL.
        Ethical challenges with the left ventricular assist device as a destination therapy.
        Philos Ethics Humanit Med. 2008; 3: 20
        • Magnetta DA
        • Kang J
        • Wearden PD
        • Smith KJ
        • Feingold B.
        Cost-effectiveness of ventricular assist device destination therapy for advanced heart failure in Duchenne muscular dystrophy.
        Pediatr Cardiol. 2018; 39: 1242-1248
        • Wells D
        • Rizwan R
        • Jefferies JL
        • et al.
        Heart transplantation in muscular dystrophy patients: Is it a viable option?.
        Circ Heart Fail. 2020; 13e005447
        • Moayedi Y
        • Ross HJ.
        Keeping an open mind: heart transplant in patients with muscular dystrophy.
        Circ Heart Fail. 2020; 13e005872